- Summit Therapeutics specializes in developing innovative therapeutic solutions for oncology and infectious diseases.
- Their flagship drug candidate, Ivonescimab, is in phase 3 clinical trials and shows promise in treating non-small cell lung cancer.
- The company’s Ivonescimab, a bispecific antibody, is supported by a partnership with Akeso. Ivonescimab targets PD-1 and VEGF pathways, potentially treating NSCLC and other cancers.
- Summit’s promising clinical trials, HARMONi and HARMONi-3, focus on advanced lung cancers and aim for FDA approval.
- SMMT is a strong buy because of ivonescimab’s potential in oncology and the company’s proven leadership under Robert Duggan.
Summit Therapeutics Inc. (NASDAQ:SMMT) discovers, develops, and commercializes therapeutic solutions in oncology. Currently, SMMT’s flagship drug candidate is Ivonescimab, which is in phase 3 clinical trials in the US. This bispecific antibody targets the PD-1 protein receptor and boosts the immune system’s response to fight against tumors. Additionally, the drug blocks the VEGF pathway and hinders tumor growth, so it’s a dual-action mechanism for non-small cell lung cancer [NSCLC]. Since this underlying dynamic affects several types of cancers, Ivonescimab’s indications can extend beyond NSCLC. SMMT acquired the in-licensing rights for Ivonescimab from Akeso after Robert Duggan took over. I believe SMMT is a “strong buy” due to this considerable potential in oncology despite the inherent biotech risks.
READ FULL ARTICLE HERE!
